Osborne Partners Capital Management LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.4% during the fourth quarter, HoldingsChannel reports. The firm owned 61,822 shares of the company’s stock after selling 1,511 shares during the period. Johnson & Johnson accounts for 1.2% of Osborne Partners Capital Management LLC’s portfolio, making the stock its 22nd biggest position. Osborne Partners Capital Management LLC’s holdings in Johnson & Johnson were worth $7,978,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of JNJ. Vanguard Group Inc increased its position in shares of Johnson & Johnson by 1.5% during the third quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock worth $29,490,100,000 after purchasing an additional 3,235,861 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 1.5% during the third quarter. Vanguard Group Inc. now owns 213,433,449 shares of the company’s stock worth $29,490,100,000 after purchasing an additional 3,235,861 shares in the last quarter. Morgan Stanley increased its position in shares of Johnson & Johnson by 6.3% during the third quarter. Morgan Stanley now owns 22,920,470 shares of the company’s stock worth $3,166,921,000 after purchasing an additional 1,352,484 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of Johnson & Johnson by 2,178.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 649,040 shares of the company’s stock valued at $83,759,000 after acquiring an additional 620,558 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. increased its position in shares of Johnson & Johnson by 58.2% in the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 1,602,167 shares of the company’s stock valued at $221,371,000 after acquiring an additional 589,288 shares during the period. 66.91% of the stock is currently owned by institutional investors and hedge funds.

NYSE JNJ opened at $136.91 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.13 and a current ratio of 1.44. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.99. The firm has a market capitalization of $368.09 billion, a P/E ratio of 16.74, a PEG ratio of 2.37 and a beta of 0.67.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.07. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The firm had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. During the same period in the prior year, the firm earned $2.06 EPS. The firm’s revenue was up .1% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 11th. Shareholders of record on Tuesday, May 28th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 2.78%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.90. The ex-dividend date is Friday, May 24th. Johnson & Johnson’s dividend payout ratio is presently 44.01%.

Several equities analysts recently issued reports on JNJ shares. Zacks Investment Research downgraded Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. Barclays reissued an “equal weight” rating and issued a $135.00 target price (down from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Citigroup upped their target price on Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a research report on Monday, February 25th. Raymond James upped their target price on Johnson & Johnson from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. Finally, Morgan Stanley upped their target price on Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 17th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Johnson & Johnson has a consensus rating of “Buy” and an average target price of $146.90.

COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Stake Lessened by Osborne Partners Capital Management LLC” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://theolympiareport.com/2019/05/16/johnson-johnson-jnj-stake-lessened-by-osborne-partners-capital-management-llc.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: What are economic reports?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.